Stemcyte, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.stemcyte.com
Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)
Phase 2
Not yet recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- Biological: hUCB
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- StemCyte, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT06040476
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
Phase 2
Completed
- Conditions
- Post-COVID SyndromePost COVID-19 ConditionLong COVID
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- StemCyte, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05682560
- Locations
- 🇺🇸
Myrak Research Center, Miami Lakes, Florida, United States
Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training
Phase 2
Terminated
- Conditions
- Spinal Cord Injuries
- Interventions
- Biological: Umbilical Cord Blood Mononuclear CellOther: Locomotor Training
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- StemCyte, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03979742
- Locations
- 🇨🇳
Hualien Tzu Chi Hospital, Hualien City, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei City, Taiwan
News
No news found